Author:
Mazzini Giulia,Le Foll Christelle,Boyle Christina N.,Garelja Michael L.,Zhyvoloup Alexander,Miller Matthew E.T.,Hay Debbie L.,Raleigh Daniel P.,Lutz Thomas A.
Funder
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
National Institutes of Health
Wellcome Trust
Reference86 articles.
1. Amylin: pharmacology, physiology, and clinical potential;Hay;Pharmacol. Rev.,2015
2. The physiological control of eating: signals, neurons, and networks;Watts;Physiol. Rev.,2022
3. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial;Frias;Lancet,2023
4. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial;Lau;Lancet,2021
5. Efficacy and safety of AM833 for weight loss: a dose-finding trial in adults with overweight/obesity;David,2020